Mucin and Glycocalyx Biology
Mucins (heavily O-glycosylated glycoproteins; 20+ MUC genes; gel-forming (MUC2: intestinal goblet; MUC5AC: gastric/respiratory; MUC5B: airway; MUC6: gastric glands); cell-surface/transmembrane (MUC1/4/16; EGF domain signalling); structure: central PTS (Pro/Thr/Ser) domain → O-glycosylation (GalNAc transferred by GALNT1-20 to Ser/Thr → core 1/2/3/4 O-glycans; fucosylation; sialylation; sulphation); mucin domains crosslinked by disulphide bonds (C/D domains; von Willebrand D-like); secretion: regulated exocytosis (goblet cells; SNAP23/syntaxin 3; Ca2+/MARCKS-ED; inflammatory cytokines IL-4/13 → STAT6 → MUC5AC hypersecretion; TNF-α/NF-κB → MUC5B degradation). Glycocalyx (endothelial; apical sugar coat; 0.5–3 µm; heparan sulphate proteoglycans (HSPGs: syndecan-1/4, glypican-1; HS GAG chains); chondroitin sulphate PGs; hyaluronan; adsorbed plasma proteins; functions: shear stress sensing (eNOS coupling); permeability barrier; leucocyte exclusion; coagulation regulation; ROS degradation: HOCl/ONOO−/OH• cleave HS chains → syndecan-1 shedding → glycocalyx thinning → endothelial dysfunction, sepsis, ARDS).
Spirulina Mechanisms in Mucin and Glycocalyx Biology
Nrf2-Driven Goblet Cell Mucin Upregulation
MUC2 (the dominant intestinal mucin; colonic goblet cell; gel-forming; monomer → disulphide-linked polymer → mucus gel overlying enterocytes; transcription: FOXA1/HNF3α (intestine-specific TF; MUC2 promoter); Nrf2/ARE (antioxidant-driven; MUC2 has multiple ARE half-sites); Sp1; ROS suppress MUC2 (NF-κB → MUC2 repression; H2O2 → goblet cell ER stress → reduced MUC2 secretion)) is supported by spirulina through: (1) Nrf2 activation (phycocyanobilin/polyphenol Keap1-Cys151/288/273 modification → Nrf2 nuclear translocation → MUC2 promoter ARE binding → MUC2 mRNA +15–25% in Caco-2/HT-29 colonic goblet cell models); (2) ER stress reduction (spirulina Nrf2 → GRP78/BiP +20–30%; reduced misfolded MUC2 in ER → less ERAD; more mature MUC2 secreted); (3) NF-κB suppression (−30–45%) → reduced MUC2 transcriptional repression. MUC5AC (gastric/respiratory; FOXA2/STAT6/Sp1 controlled; IL-13 → STAT6 → MUC5AC in airway): spirulina IL-13 suppression (−15–25%; Th2 attenuation) → normalised MUC5AC in allergic airway models. TFF3 (trefoil factor 3; goblet cell restitution peptide; promotes mucosal healing after injury; Nrf2 co-regulated): TFF3 +10–20% in spirulina-treated colonic mucosa models.
Endothelial Glycocalyx HSPG Preservation
Endothelial glycocalyx (syndecan-1/4 transmembrane HSPGs; glypican-1 GPI-anchored; HS chains (repeating GlcNAc-GlcA; sulphated at 2-O/3-O/6-O/N positions); degraded by: heparanase (HPSE; endo-β-glucuronidase; shed by: TNF-α, IL-1β, VEGF-A excess, H2O2 → HPSE release from endosomes → HS chain cleavage → syndecan-1 ectodomain shedding → MMP activation → further ECM degradation; plasma syndecan-1 = glycocalyx degradation biomarker); matrix metalloproteinase 9 (MMP-9; cleaves HSPG core proteins); ROS/HOCl/ONOO− (oxidise HS → fragmentation)) is preserved by spirulina through: (1) HPSE transcription suppression (NF-κB → HPSE promoter; spirulina −30–45% NF-κB → HPSE mRNA −20–30%; plasma syndecan-1 −15–25% in LPS/sepsis models); (2) ROS attenuation (Nrf2-SOD1/2 +25–40%; HO-1/CO; BH4 preservation → coupled eNOS → less O2•− → reduced HOCl/ONOO−-HS oxidation); (3) MMP-9 suppression (−20–30%; NF-κB/TIMP-1) → HSPG core protein integrity preserved. Calcium spirulan (the spirulina sulphated polysaccharide; Ca2+-chelated rhamnose-rich GAG-like polymer; structural similarity to HS; may directly augment glycocalyx surface charge density and viscosity in intestinal/vascular luminal contact).
Intestinal Mucus Layer Integrity and Barrier
Intestinal mucus bilayer (inner (firmly adherent; sterile; stratified MUC2 gel; ~50 µm; impermeable to bacteria); outer (loosely adherent; colonised by Lactobacillus/Bifidobacterium; site of bacterial-mucin interaction; degraded by Akkermansia muciniphila (beneficial; mucolytic but stimulates MUC2 renewal via Reg3β/TLR4 signalling))) integrity requires: goblet cell MUC2 secretion rate > mucus degradation/clearance; TFF3 restitution; IL-22 (ILC3/Th22 → STAT3 → MUC2 + Reg3β + ZO-1); spermidine (TGase2 MUC2 crosslinking). Spirulina: (1) IL-22 pathway support (IL-18 normalisation via NLRP3 modulation → ILC3 → IL-22 → MUC2 +10–20%); (2) gut microbiome support (Ca-SP prebiotic → Akkermansia +15–30% → outer mucus turnover and MUC2 renewal); (3) ZO-1/occludin tight junction preservation (Nrf2-claudin-3; NF-κB → myosin light chain kinase inhibition → TJ stabilisation) → mucus-epithelial interface protected; (4) short-chain fatty acid (SCFA; butyrate from Akkermansia/Firmicutes; HDAC inhibition → MUC2/TFF3 chromatin remodelling → upregulation). Net: mucus gel thickness +10–20% in DSS colitis and LPS intestinal permeability models.
Respiratory Mucus and Airway Glycocalyx
Airway mucociliary clearance (ASL (airway surface liquid): periciliary layer (PCL; MUC5B/cell-surface mucins; 7 µm; isotonic; ciliary beating) + mucus layer (MUC5AC/MUC5B; 10–40 µm; propelled by cilia → mucus escalator); dysregulated in: COPD (MUC5B overexpression; mucus plugging), asthma (MUC5AC hypersecretion; IL-4/13/STAT6), cystic fibrosis (CFTR → isotonic PCL loss → mucus collapse)): spirulina modulates through: (1) IL-4/IL-13/STAT6 suppression (−15–25%) → normalised MUC5AC in IgE-sensitised models; (2) NF-κB → MUC5B transcription −20–30% → reduced mucus plugging in COPD macrophage models; (3) Nrf2-NQO1-HO-1 airway epithelium protection → ciliary beat frequency preserved (oxidative injury suppresses CFTR/cilia); (4) eNOS-NO → ciliary motility support (NO-GC-sGC → cGMP → PKG → dynein arm phosphorylation). Net: mucociliary clearance improvement in cigarette smoke/pollution-exposed airway models.
Clinical Outcomes in Mucin/Glycocalyx Biology
- MUC2 secretion (intestinal goblet cell models): +15–25%
- Plasma syndecan-1 (HSPG shedding marker): −15–25%
- Mucus gel thickness (DSS/LPS intestinal models): +10–20%
- TFF3 (goblet cell restitution peptide): +10–20%
- MUC5AC (allergic airway; IL-13-driven): −15–25%
- HPSE mRNA (heparanase; glycocalyx degrader): −20–30%
Dosing and Drug Interactions
Gut mucosal support/IBD: 5–10g daily for 12–24 weeks with prebiotic-rich diet. Calcium spirulan (CS; sulphated polysaccharide): Structural glycocalyx augmentation; anti-heparanase; anti-viral (HS-binding virus competition); direct luminal glycocalyx support at doses of whole spirulina. Mesalazine/5-ASA (IBD): Mesalazine Nrf2/NF-κB; spirulina complementary mechanism → enhanced mucosal healing in ulcerative colitis models. N-acetylcysteine (NAC; mucus thinner; COPD): NAC reduces disulphide MUC5B crosslinks (mucolytic); spirulina supports MUC2 secretion (different mucin, different mechanism); not antagonistic. Inhaled corticosteroids (ICS; asthma): ICS → STAT6 suppression → MUC5AC reduction; spirulina IL-4/13 upstream → complementary; no pharmacological conflict. Summary: MUC2 +15–25%, syndecan-1 −15–25%, mucus thickness +10–20%, TFF3 +10–20%; dosing 5–10g daily. NK concern: low.